Results from two clinical trials show that combining a procedure called TACE with an immunotherapy drug and angiogenesis inhibitor improves how long people with intermediate-stage liver cancer live without their disease returning or getting worse.
Certain inherited genetic changes are likely involved in the development of some cancers in children, a new study shows. The changes, called structural variants, were linked with a small percentage of children with neuroblastoma, Ewing sarcoma, and osteosarcoma.
An AI-based tool called SCORPIO more accurately predicted whether cancer patients’ tumors would respond to checkpoint inhibitors than currently available tests, a new study found. It also predicted how long patients would live after treatment.
Unusual results from prenatal testing can indicate that the mother has cancer, a new study has found. The study also suggests that whole-body imaging as part of the follow-up on abnormal results can accurately identify these cancers.
The injectable form of nivolumab, called Opdivo Qvantig, is quicker and easier to give, several oncologists said, and is just as effective as the intravenous form. Injectable forms of other immunotherapies are also on the horizon.
Many U.S. doctors aren’t using the recommended initial treatments for their patients with hormone-sensitive metastatic prostate cancer, a new study has found. Often, it’s because they aren’t up to date on the latest treatment recommendations or because of side effect concerns.
Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.